Compare ATYR & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATYR | VATE |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | United States |
| Employees | 59 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 74.0M |
| IPO Year | N/A | 1996 |
| Metric | ATYR | VATE |
|---|---|---|
| Price | $0.84 | $4.08 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.20 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 12.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,107,100,000.00 |
| Revenue This Year | $9,628.95 | N/A |
| Revenue Next Year | $156.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.64 | $4.05 |
| 52 Week High | $7.29 | $9.01 |
| Indicator | ATYR | VATE |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 27.57 |
| Support Level | $0.82 | $4.11 |
| Resistance Level | $0.85 | $5.37 |
| Average True Range (ATR) | 0.07 | 0.27 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 7.78 | 11.84 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.